{"Genomes": [0], "of": [1, 21, 38, 63, 119, 251, 274], "tumors": [2, 29], "that": [3, 24], "are": [4, 30], "deficient": [5], "in": [6, 65, 138, 216, 235], "DNA": [7], "mismatch": [8], "repair": [9], "(dMMR)": [10], "have": [11], "high": [12], "microsatellite": [13], "instability": [14], "(MSI-H)": [15], "and": [16, 121, 163, 198], "harbor": [17], "hundreds": [18], "to": [19, 33, 184, 195, 209, 226], "thousands": [20], "somatic": [22], "mutations": [23], "encode": [25], "potential": [26], "neoantigens.": [27], "Such": [28], "therefore": [31], "likely": [32], "be": [34], "immunogenic,": [35], "triggering": [36], "upregulation": [37], "immune": [39], "checkpoint": [40], "proteins.": [41], "Pembrolizumab,": [42], "an": [43], "anti\u2012programmed": [44], "death-1": [45, 253], "monoclonal": [46], "antibody,": [47], "has": [48], "antitumor": [49], "activity": [50], "against": [51], "MSI-H/dMMR": [52, 72, 78, 265], "cancer.": [53, 267], "We": [54], "report": [55], "data": [56], "from": [57], "the": [58, 116, 167, 248], "phase": [59], "II": [60], "KEYNOTE-158": [61], "study": [62, 246], "pembrolizumab": [64, 89, 256, 275], "patients": [66, 74, 218, 221, 258], "with": [67, 75, 85, 159, 255, 259, 271], "previously": [68, 260], "treated,": [69], "advanced": [70, 79], "noncolorectal": [71, 80, 266], "cancer.Eligible": [73], "histologically/cytologically": [76], "confirmed": [77], "cancer": [81], "who": [82], "experienced": [83], "failure": [84], "prior": [86], "therapy": [87, 120, 254], "received": [88], "200": [90], "mg": [91], "once": [92], "every": [93, 112, 122], "3": [94, 225], "weeks": [95, 114, 124], "for": [96, 115], "2": [97], "years": [98], "or": [99, 105, 263], "until": [100], "disease": [101], "progression,": [102], "unacceptable": [103], "toxicity,": [104], "patient": [106], "withdrawal.": [107], "Radiologic": [108], "imaging": [109], "was": [110, 130, 173, 179, 189, 202, 269], "performed": [111], "9": [113], "first": [117], "year": [118], "12": [123], "thereafter.": [125], "The": [126], "primary": [127], "end": [128], "point": [129], "objective": [131], "response": [132, 177], "rate": [133, 178], "per": [134], "Response": [135], "Evaluation": [136], "Criteria": [137], "Solid": [139], "Tumors": [140], "(RECIST)": [141], "version": [142], "1.1,": [143], "as": [144], "assessed": [145], "by": [146], "independent": [147], "central": [148], "radiologic": [149], "review.Among": [150], "233": [151], "enrolled": [152], "patients,": [153], "27": [154], "tumor": [155], "types": [156], "were": [157, 239], "represented,": [158], "endometrial,": [160], "gastric,": [161], "cholangiocarcinoma,": [162], "pancreatic": [164], "cancers": [165], "being": [166], "most": [168], "common.": [169], "Median": [170, 186], "follow": [171], "up": [172], "13.4": [174], "months.": [175], "Objective": [176], "34.3%": [180], "(95%": [181, 192, 205], "CI,": [182, 193, 206], "28.3%": [183], "40.8%).": [185], "progression-free": [187], "survival": [188, 201], "4.1": [190], "months": [191, 204, 208], "2.4": [194], "4.9": [196], "months)": [197], "median": [199], "overall": [200], "23.5": [203], "13.5": [207], "not": [210], "reached).": [211], "Treatment-related": [212], "adverse": [213, 229, 244], "events": [214], "occurred": [215, 234], "151": [217], "(64.8%).": [219], "Thirty-four": [220], "(14.6%)": [222], "had": [223], "grade": [224], "5": [227, 232], "treatment-related": [228, 242], "events.": [230], "Grade": [231], "pneumonia": [233], "one": [236], "patient;": [237], "there": [238], "no": [240], "other": [241], "fatal": [243], "events.Our": [245], "demonstrates": [247], "clinical": [249], "benefit": [250], "anti-programmed": [252], "among": [257], "treated": [261], "unresectable": [262], "metastatic": [264], "Toxicity": [268], "consistent": [270], "previous": [272], "experience": [273], "monotherapy.": [276]}